Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23605010 | 0.91 | PDE4B (0.31) | PDE4BGAA | |
| SCHEMBL26508138 | 0.91 | PDE4B (0.31) | PDE4BGAA | |
| SCHEMBL16003016 | 0.91 | CXCR2 (0.33) | PDE4B | |
| SCHEMBL15723424 | 0.90 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL26481205 | 0.89 | HDAC3 (0.33) | PDE4BGAAHDAC3HDAC4HDAC1 | |
| SCHEMBL806626 | 0.89 | CCNT1 (0.33) | PDE4BCCNT1CDK9 | |
| SCHEMBL806691 | 0.89 | GAA (0.33) | PDE4BGAAHDAC3HDAC4HDAC1 | |
| SCHEMBL23736080 | 0.86 | HDAC3 (0.34) | PDE4BGAAHDAC3HDAC4HDAC1 | |
| SCHEMBL25985625 | 0.85 | HDAC3 (0.32) | PDE4BHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15727211 | 0.84 | CCNT1 (0.35) | PDE4BCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| US-20200262869-A1 | PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE THEREOF | GENENTECH, INC. | 2020-08-20 | — | — | US | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | PDE4B 3025/4885CREBBP 192/4885GAA 526/4885 |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PDE4B 3216/4885CREBBP 264/4885GAA 978/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | PDE4B 3216/4885CREBBP 264/4885GAA 978/4885 |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PDE4B 3216/4885CREBBP 264/4885GAA 978/4885 |
| US-20200262869-A1 | PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE THEREOF | SPAST, PEPD, DNPEP | PDE4B 3009/4885CREBBP 1100/4885GAA 504/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PDE4B 3216/4885CREBBP 264/4885GAA 978/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PDE4B 3216/4885CREBBP 264/4885GAA 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.